Report cover image

Systemic Inflammatory Response Syndrome Pipeline Analysis Report 2025

Publisher Expert Market Research
Published May 25, 2025
Length 200 Pages
SKU # EMAR20147063

Description

Systemic inflammatory response syndrome (SIRS) refers to the body’s overwhelming response to a stressor. It can be caused by an infection, trauma, or a worsening health condition, among others. Systemic inflammatory response syndrome requires immediate treatment in a hospital. The growing incidence of stressors such as sepsis, trauma, or pancreatitis coupled with the expanding aging population and increasing surgical interventions are fueling the demand for effective treatments. Moreover, the rising advancements in biotechnology, including CRISPR, mRNA technology, and advanced biologics, are encouraging investment in the pipeline.

Report Coverage

The Systemic Inflammatory Response Syndrome Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into systemic inflammatory response syndrome therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for systemic inflammatory response syndrome. The systemic inflammatory response syndrome report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The systemic inflammatory response syndrome pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with systemic inflammatory response syndrome treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to systemic inflammatory response syndrome.

Systemic Inflammatory Response Syndrome Drug Pipeline Outlook

Systemic inflammatory response syndrome (SIRS) is an inflammatory state caused by the body's reaction to an infectious or noninfectious agent. The exaggerated defense response of the body can lead to organ failure and even death. If SIRS occurs due to a known infection, it's called sepsis. Common symptoms include edema in the affected parts of the body, intense fatigue and/or pain, fast heart rate, chills, or skin rash, among others.

Systemic Inflammatory Response Syndrome therapeutics include antibiotics or antiviral agents if SIRS is triggered by bacterial or viral infections, respectively. Systemic inflammatory response syndrome emerging drugs like siRNA or mRNA-based therapies, cytokine inhibitors, and stem cell therapies are expected to diversify therapeutic options and augment treatment market growth. Further, the increasing investment in clinical trials to evaluate novel therapies along with the rising focus on personalized medicine are anticipated to support the drug pipeline expansion in the coming years.

Systemic Inflammatory Response Syndrome Epidemiology

Systemic inflammatory response syndrome is a life-threatening condition characterized by inflammation throughout the body. Prompt treatment can help in the complete recovery of the patient. However, nearly 7% of SIRS patients die from the syndrome, with mortality rates for sepsis estimated to be 28% for septic shock, 9.2% for severe sepsis, and 1.3% for sepsis.

Owing to the nonspecific nature of the definition of systemic inflammatory response syndrome, the exact incidence of the condition is unknown but is expected to be very high.

Systemic Inflammatory Response Syndrome – Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of systemic inflammatory response syndrome drug candidates based on several segmentations including:

By Phase
  • Late-Stage Products (Phase 3 and Phase 4)
  • Mid-Stage Products (Phase 2)
  • Early-Stage Products (Phase I)
  • Preclinical and Discovery Stage Products
By Drug Class
  • Small Molecules
  • Biologics
  • Peptides
  • RNA-Based Therapies
  • Cell-Based Therapies
  • Nanoparticle-Based Drugs
  • Synthetic Polymers
By Route of Administration
  • Oral
  • Parenteral
  • Others
Systemic Inflammatory Response Syndrome – Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase II covers a major share of the total clinical trials, with a substantial number of systemic inflammatory response syndrome drugs undergoing clinical development.

Systemic Inflammatory Response Syndrome – Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under systemic inflammatory response syndrome pipeline analysis include small molecules, biologics, peptides, RNA-based therapies, cell-based therapies, nanoparticle-based drugs, and synthetic polymers. The systemic inflammatory response syndrome report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for systemic inflammatory response syndrome.

Systemic Inflammatory Response Syndrome Clinical Trials Therapeutic Assessment – Competitive Dynamics

The EMR report for the systemic inflammatory response syndrome drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed systemic inflammatory response syndrome therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. below is the list of a few players involved in systemic inflammatory response syndrome clinical trials:
  • Healios K.K.
  • Grand Medical Pty Ltd.
  • Vivacelle Bio
  • Op-T LLC
  • Novartis Pharmaceuticals
  • Mundipharma Research Limited
Systemic Inflammatory Response Syndrome – Emerging Drugs Profile

Major drugs currently in the drug pipeline are as follows:

Drug: VBI-S

Sponsored by Vivacelle Bio, the objective of this randomized clinical trial is to investigate the efficacy and safety of the systemic inflammatory response syndrome drug candidate VBI-S in patients experiencing hypovolemia with septic shock. The study is under Phase III clinical development and has an estimated 46 participants.

Drug: MultiStem®

Healios K.K. is conducting a Phase II study aimed at examining the efficacy and safety of the investigational injectable drug MultiStem® to treat trauma induced multiple organ failure/systemic inflammatory response syndrome. The clinical trial has enrolled about 156 subjects and is expected to be completed by December 2025.

Reasons To Buy This Report

The Systemic Inflammatory Response Syndrome Drug Report provides a strategic overview of the latest and future landscape of treatments for systemic inflammatory response syndrome. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within systemic inflammatory response syndrome pipeline insights.

Key Questions Answered in the Systemic Inflammatory Response Syndrome – Pipeline Insight Report
  • What is the current landscape of systemic inflammatory response syndrome disease pipeline drugs?
  • Which companies/institutions are developing systemic inflammatory response syndrome disease emerging drugs?
  • How many phase II drugs are currently present in systemic inflammatory response syndrome disease pipeline drugs?
  • Which company is leading the systemic inflammatory response syndrome disease pipeline development activities?
  • What is the current systemic inflammatory response syndrome disease therapeutic assessment?
  • What are the opportunities and challenges present in the systemic inflammatory response syndrome disease drug pipeline landscape?
  • What is the efficacy and safety profile of systemic inflammatory response syndrome disease pipeline drugs?
  • Which companies/institutions are involved in systemic inflammatory response syndrome disease collaborations aimed at providing enhanced therapeutic alternatives for patients?
  • What are the geographies covered for clinical trials in systemic inflammatory response syndrome disease?
Related Reports

Sepsis Diagnostics Market

Clinical Trials Market

Table of Contents

200 Pages
1 Preface
1.1 Introduction
1.2 Objectives of the Study
1.3 Research Methodology & Assumptions
2 Executive Summary
3 Overview of Systemic Inflammatory Response Syndrome
3.1 Signs and Symptoms
3.2 Causes
3.3 Risk Factors
3.4 Diagnosis
3.5 Treatment
4 Patient Profile: Systemic Inflammatory Response Syndrome
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Systemic Inflammatory Response Syndrome: Epidemiology Snapshot
5.1 Systemic Inflammatory Response Syndrome Incidence by Key Markets
5.2 Systemic Inflammatory Response Syndrome – Patients Seeking Treatment in Key Markets
6 Systemic Inflammatory Response Syndrome: Market Dynamics
6.1 Market Drivers and Constraints
6.2 SWOT Analysis
7 Systemic Inflammatory Response Syndrome: Key Facts Covered
7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
7.2 Top Countries Contributing to Clinical Trials in Europe
7.3 Top Countries Contributing to Clinical Trials in North America
7.4 Top Countries Contributing to Clinical Trials in Other Regions
8 Systemic Inflammatory Response Syndrome, Drug Pipeline Assessment
8.1 Assessment by Treatment Type
8.2 Assessment by Route of Administration
8.3 Assessment by Drug Class
9 EMR Drug Pipeline Comparative Analysis
9.1 List of Systemic Inflammatory Response Syndrome Pipeline Drugs
9.1.1 By Company
9.1.2 By Phase
9.1.3 By Indication
9.1.4 By Trial Status
9.1.5 By Funder Type
9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
10 Systemic Inflammatory Response Syndrome Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
10.1 Comparative Analysis for Late-Stage Drugs
10.1.1 Study Type
10.1.2 Recruitment Status
10.1.3 Company
10.1.4 Funder Type
10.2 Product Level Analysis*
10.2.1 Drug: VBI-S
10.2.1.1 Product Description
10.2.1.2 Trial ID
10.2.1.3 Sponsor Name
10.2.1.4 Study Type
10.2.1.5 Drug Class
10.2.1.6 Eligibility Criteria
10.2.1.7 Study Record Dates
10.2.1.7.1 First Submitted
10.2.1.7.2 First Posted
10.2.1.7.3 Last Update Posted
10.2.1.7.4 Last Verified
10.2.1.8 Indication
10.2.1.9 Study Design
10.2.1.10 Recruitment Status
10.2.1.11 Enrollment (Estimated)
10.2.1.12 Location Countries
10.2.1.13 Recent Results
10.2.2 Drug: Angiotensin II and hydrocortisone sodium succinate
10.2.3 Other Drugs
11 Systemic Inflammatory Response Syndrome Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
11.1 Comparative Analysis for Mid-Stage Drugs
11.1.1 Study Type
11.1.2 Recruitment Status
11.1.3 Company
11.1.4 Funder Type
11.2 Product Level Analysis*
11.2.1 Biological: MultiStem
11.2.1.1 Product Description
11.2.1.2 Trial ID
11.2.1.3 Sponsor Name
11.2.1.4 Study Type
11.2.1.5 Drug Class
11.2.1.6 Eligibility Criteria
11.2.1.7 Study Record Dates
11.2.1.7.1 First Submitted
11.2.1.7.2 First Posted
11.2.1.7.3 Last Update Posted
11.2.1.7.4 Last Verified
11.2.1.8 Indication
11.2.1.9 Study Design
11.2.1.10 Recruitment Status
11.2.1.11 Enrollment (Estimated)
11.2.1.12 Location Countries
11.2.1.13 Recent Results
11.2.2 Drug: STC314 Injection
11.2.3 Other Drugs
12 Systemic Inflammatory Response Syndrome Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
12.1 Comparative Analysis for Early-Stage Drugs
12.1.1 Study Type
12.1.2 Recruitment Status
12.1.3 Company
12.1.4 Funder Type
12.2 Product Level Analysis*
12.2.1 Drug: OPT101
12.2.1.1 Product Description
12.2.1.2 Trial ID
12.2.1.3 Sponsor Name
12.2.1.4 Study Type
12.2.1.5 Drug Class
12.2.1.6 Eligibility Criteria
12.2.1.7 Study Record Dates
12.2.1.7.1 First Submitted
12.2.1.7.2 First Posted
12.2.1.7.3 Last Update Posted
12.2.1.7.4 Last Verified
12.2.1.8 Indication
12.2.1.9 Study Design
12.2.1.10 Recruitment Status
12.2.1.11 Enrollment (Estimated)
12.2.1.12 Location Countries
12.2.2 Drug: Alirocumab
12.2.3 Other Drugs
13 Systemic Inflammatory Response Syndrome Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
13.1.1 Study Type
13.1.2 Recruitment Status
13.1.3 Company
13.1.4 Funder Type
13.2 Product Level Analysis*
13.2.1 Drug 1
13.2.1.1 Product Description
13.2.1.2 Trial ID
13.2.1.3 Sponsor Name
13.2.1.4 Study Type
13.2.1.5 Drug Class
13.2.1.6 Eligibility Criteria
13.2.1.7 Study Record Dates
13.2.1.7.1 First Submitted
13.2.1.7.2 First Posted
13.2.1.7.3 Last Update Posted
13.2.1.7.4 Last Verified
13.2.1.8 Indication
13.2.1.9 Study Design
13.2.1.10 Recruitment Status
13.2.1.11 Enrollment (Estimated)
13.2.1.12 Location Countries
13.2.2 Other Drugs
14 Systemic Inflammatory Response Syndrome, Key Drug Pipeline Companies
14.1 Healios K.K.
14.1.1 Company Snapshot
14.1.2 Pipeline Product Portfolio
14.1.3 Financial Analysis
14.1.4 Recent News and Developments
14.2 Grand Medical Pty Ltd.
14.2.1 Company Snapshot
14.2.2 Pipeline Product Portfolio
14.2.3 Financial Analysis
14.2.4 Recent News and Developments
14.3 Vivacelle Bio
14.3.1 Company Snapshot
14.3.2 Pipeline Product Portfolio
14.3.3 Financial Analysis
14.3.4 Recent News and Developments
14.4 Op-T LLC
14.4.1 Company Snapshot
14.4.2 Pipeline Product Portfolio
14.4.3 Financial Analysis
14.4.4 Recent News and Developments
14.5 Novartis Pharmaceuticals
14.5.1 Company Snapshot
14.5.2 Pipeline Product Portfolio
14.5.3 Financial Analysis
14.5.4 Recent News and Developments
14.6 Mundipharma Research Limited
14.6.1 Company Snapshot
14.6.2 Pipeline Product Portfolio
14.6.3 Financial Analysis
14.6.4 Recent News and Developments
15 Regulatory Framework for Drug Approval, By Region
16 Terminated or Suspended Pipeline Products

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us